Celgene Corp. Price Target Raised to $197.00 at Jefferies Group (CELG)
Equities researchers at Jefferies Group hoisted their target price on shares of Celgene Corp. (NASDAQ:CELG) from $185.00 to $197.00 in a research report issued on Tuesday, AnalystRatings.NET reports. Jefferies Group’s price target suggests a potential upside of 17.94% from the stock’s previous close.
A number of other firms have also recently commented on CELG. Analysts at Brean Capital raised their price target on shares of Celgene Corp. from $191.00 to $233.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Barclays raised their price target on shares of Celgene Corp. from $173.00 to $182.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Finally, analysts at Nomura initiated coverage on shares of Celgene Corp. in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and twenty have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $166.40.
Celgene Corp. (NASDAQ:CELG) traded up 1.30% during mid-day trading on Tuesday, hitting $167.04. The stock had a trading volume of 3,895,530 shares. Celgene Corp. has a one year low of $96.30 and a one year high of $174.66. The stock has a 50-day moving average of $165.9 and a 200-day moving average of $150.. The company has a market cap of $68.832 billion and a P/E ratio of 47.48. Celgene Corp. also was the recipient of some unusual options trading activity on Monday. Stock investors acquired 26,795 call options on the stock. This is an increase of approximately 291% compared to the typical daily volume of 6,854 call options.
Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, October 24th. The company reported $1.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. On average, analysts predict that Celgene Corp. will post $6.00 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.